Equities Analysts Set Expectations for OVID Q1 Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a report issued on Wednesday, March 12th. William Blair analyst S. Schram anticipates that the company will post earnings of ($0.18) per share for the quarter. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.19 million.

Several other equities analysts also recently issued reports on OVID. Wedbush reiterated an “outperform” rating and set a $3.00 price objective (down from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a research report on Wednesday, December 4th. Finally, Oppenheimer upgraded Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 target price for the company in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Ovid Therapeutics has an average rating of “Buy” and a consensus price target of $3.20.

Ovid Therapeutics Stock Performance

Shares of NASDAQ OVID opened at $0.43 on Thursday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $0.65 and a 200-day simple moving average of $0.96. The company has a market cap of $30.81 million, a PE ratio of -0.92 and a beta of 0.29. Ovid Therapeutics has a 12-month low of $0.42 and a 12-month high of $3.45.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC raised its stake in Ovid Therapeutics by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares during the period. XTX Topco Ltd increased its stake in shares of Ovid Therapeutics by 46.2% in the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after acquiring an additional 12,076 shares during the last quarter. FMR LLC increased its stake in shares of Ovid Therapeutics by 1,907.4% in the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after acquiring an additional 47,723 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in shares of Ovid Therapeutics in the fourth quarter worth $65,000. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.